30 research outputs found
Multichannel Sleep Stage Classification and Transfer Learning using Convolutional Neural Networks
Current sleep medicine relies on the analysis of polysomnographic measurements, comprising amongst others electroencephalogram (EEG), electromyogram (EMG), and electrooculogram (EOG) signals. This analysis currently requires supervision of a trained expert. Convolutional neural networks (CNN) provide an interesting framework to automated classification of sleep epochs based on raw EEG, EOG and EMG waveforms. In this study, we apply CNN approaches from the literature to four databases from pathological and physiological subjects. The best performing model resulted in Cohenâs Kappa of k = 0.75 on healthy subjects and k = 0.64 on patients suffering from a variety of sleep disorder. Further, we show the advantages of using additional sensor data such as EOG and EMG. Last, to cope with smaller datasets of less prevalent diseases, we propose a transfer learning procedure using large freely available databases for pre-training. This procedure is demonstrated using a private REM Behaviour Disorder database, improving sleep classification by 24.4%
Reward insensitivity is associated with dopaminergic deficit in rapid eye movement sleep behaviour disorder
Idiopathic rapid eye movement sleep behaviour disorder (iRBD) has now been established as an important marker of the prodromal stage of Parkinsonâs disease and related synucleinopathies. However, although dopamine transporter single photon emission computed tomography (SPECT) has been used to demonstrate the presence of nigro-striatal deficit in iRBD, quantifiable correlates of this are currently lacking. Sensitivity to rewarding stimuli is reduced in some people with Parkinsonâs disease, potentially contributing to aspects of the neuropsychiatric phenotype in these individuals. Furthermore, a role for dopaminergic degeneration is suggested by the fact that reward insensitivity can be improved by dopaminergic medications. Patients with iRBD present a unique opportunity to study the relationship between reward sensitivity and early dopaminergic deficit in the unmedicated state.
Here, we investigate whether a non-invasive, objective measure of reward sensitivity might be a marker of dopaminergic status in prodromal Parkinsonâs disease by comparing with SPECT/CT measurement of dopaminergic loss in the basal ganglia. Striatal dopaminergic deficits in iRBD are associated with progression to Parkinsonian disorders. Therefore, identification of a clinically measurable correlate of this degenerative process might provide a basis for the development of novel risk stratification tools.
Using a recently developed incentivized eye-tracking task, we quantified reward sensitivity in a cohort of 41 patients with iRBD and compared this with data from 40 patients with Parkinsonâs disease and 41 healthy controls. Patients with iRBD also underwent neuroimaging with dopamine transporter SPECT/CT. Overall, reward sensitivity, indexed by pupillary response to monetary incentives, was reduced in iRBD cases compared with controls and was not significantly different to that in patients with Parkinsonâs disease. However, in iRBD patients with normal dopamine transporter SPECT/CT imaging, reward sensitivity was not significantly different from healthy controls. Across all iRBD cases, a positive association was observed between reward sensitivity and dopaminergic SPECT/CT signal in the putamen. These findings demonstrate a direct relationship between dopaminergic deficit and reward sensitivity in patients with iRBD and suggest that measurement of pupillary responses could be of value in models of risk stratification and disease progression in these individuals
Developing and validating Parkinson's disease subtypes and their motor and cognitive progression
Peer reviewedPublisher PD
Equating scores of the University of Pennsylvania smell identification test and sniffin' sticks test in patients with Parkinson's disease
Background
Impaired olfaction is an important feature in Parkinson's disease (PD) and other neurological diseases. A variety of smell identification tests exist such as âSniffinâ Sticksâ and the University of Pennsylvania Smell Identification Test (UPSIT). An important part of research is being able to replicate findings or combining studies in a meta-analysis. This is difficult if olfaction has been measured using different metrics. We present conversion methods between the: UPSIT, Sniffinâ 16, and Brief-SIT (B-SIT); and Sniffinâ 12 and Sniffinâ 16 odour identification tests.
Methods
We used two incident cohorts of patients with PD who were tested with either the Sniffinâ 16 (n = 1131) or UPSIT (n = 980) and a validation dataset of 128 individuals who took both tests. We used the equipercentile and Item Response Theory (IRT) methods to equate the olfaction scales.
Results
The equipercentile conversion suggested some bias between UPSIT and Sniffinâ 16 tests across the two groups. The IRT method shows very good characteristics between the true and converted Sniffinâ 16 (delta mean = 0.14, median = 0) based on UPSIT. The equipercentile conversion between the Sniffinâ 12 and 16 item worked well (delta mean = 0.01, median = 0). The UPSIT to B-SIT conversion showed evidence of bias but amongst PD cases worked well (mean delta = â0.08, median = 0).
Conclusion
We have demonstrated that one can convert UPSIT to B-SIT or Sniffinâ 16, and Sniffinâ 12 to 16 scores in a valid way. This can facilitate direct comparison between tests aiding future collaborative analyses and evidence synthesis
Open data from the third observing run of LIGO, Virgo, KAGRA, and GEO
The global network of gravitational-wave observatories now includes five detectors, namely LIGO Hanford, LIGO Livingston, Virgo, KAGRA, and GEO 600. These detectors collected data during their third observing run, O3, composed of three phases: O3a starting in 2019 April and lasting six months, O3b starting in 2019 November and lasting five months, and O3GK starting in 2020 April and lasting two weeks. In this paper we describe these data and various other science products that can be freely accessed through the Gravitational Wave Open Science Center at https://gwosc.org. The main data set, consisting of the gravitational-wave strain time series that contains the astrophysical signals, is released together with supporting data useful for their analysis and documentation, tutorials, as well as analysis software packages
Search for eccentric black hole coalescences during the third observing run of LIGO and Virgo
Despite the growing number of binary black hole coalescences confidently observed through gravitational waves so far, the astrophysical origin of these binaries remains uncertain. Orbital eccentricity is one of the clearest tracers of binary formation channels. Identifying binary eccentricity, however, remains challenging due to the limited availability of gravitational waveforms that include the effects of eccentricity. Here, we present observational results for a waveform-independent search sensitive to eccentric black hole coalescences, covering the third observing run (O3) of the LIGO and Virgo detectors. We identified no new high-significance candidates beyond those that have already been identified with searches focusing on quasi-circular binaries. We determine the sensitivity of our search to high-mass (total source-frame mass M > 70 Mâ) binaries covering eccentricities up to 0.3 at 15 Hz emitted gravitational-wave frequency, and use this to compare model predictions to search results. Assuming all detections are indeed quasi-circular, for our fiducial population model, we place a conservative upper limit for the merger rate density of high-mass binaries with eccentricities 0 < e †0.3 at 16.9 Gpcâ3 yrâ1 at the 90% confidence level
Aberrant functional connectivity within the basal ganglia of patients with Parkinson's disease
Resting state functional MRI (rs-fMRI) has been previously shown to be a promising tool for the assessment of early Parkinson's disease (PD). In order to assess whether changes within the basal ganglia network (BGN) are disease specific or relate to neurodegeneration generally, BGN connectivity was assessed in 32 patients with early PD, 19 healthy controls and 31 patients with Alzheimer's disease (AD). Voxel-wise comparisons demonstrated decreased connectivity within the basal ganglia of patients with PD, when compared to patients with AD and healthy controls. No significant changes within the BGN were seen in AD, when compared to healthy controls. Moreover, measures of functional connectivity extracted from regions within the basal ganglia were significantly lower in the PD group. Consistent with previous radiotracer studies, the greatest change when compared to the healthy control group was seen in the posterior putamen of PD subjects. When combined into a single component score, this method differentiated PD from AD and healthy control subjects, with a diagnostic accuracy of 81%. Rs-fMRI can be used to demonstrate the aberrant functional connectivity within the basal ganglia of patients with early PD. These changes are likely to be representative of patho-physiological basal ganglia dysfunction and are not associated with generalised neurodegeneration seen in AD. Further studies are necessary to ascertain whether this method is sensitive enough to detect basal ganglia dysfunction in prodromal PD, and its utility as a potential diagnostic biomarker for premotor and early motoric disease
Recommended from our members
Evaluation of Cerebrospinal Fluid 뱉Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal Syndrome
Publication status: PublishedFunder: National Institutes of Health Center for Alzheimer's and Related DementiasFunder: Medical Research Council; doi: http://dx.doi.org/10.13039/501100000265Funder: PSP Association; doi: http://dx.doi.org/10.13039/100011707Funder: CBD SolutionsBackground: Seed amplification assay (SAA) testing has been developed as a biomarker for the diagnosis of αâsynucleinârelated neurodegenerative disorders. Objective: The objective of this study was to assess the rate of αâsynuclein SAA positivity in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) and to analyze clinical and pathological features of SAAâpositive and ânegative cases. Methods: A total of 96 cerebrospinal fluid samples from clinically diagnosed PSP (n = 59) and CBS (n = 37) cases were analyzed using αâsynuclein SAA. Results: Six of 59 (10.2%) PSP cases were αâsynuclein SAA positive, including one case who was MSAâtype positive. An exploratory analysis showed that PSP cases who were Parkinson's diseaseâtype positive were older and had a shorter disease duration compared with SAAânegative cases. In contrast, 11 of 37 (29.7%) CBS cases were αâsynuclein SAA positive, including two cases who were MSAâtype positive. Conclusions: Our results suggest that αâsynuclein seeds can be detected in PSP and CBS using a cerebrospinal fluid αâsynuclein SAA, and in PSP this may impact on clinical course. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Comprehensive analysis of familial Parkinsonism genes in rapid-eye-movement sleep behavior disorder
Background: There is only partial overlap in the genetic background of isolated rapid-eye-movement sleep behavior disorder (iRBD) and Parkinson's disease (PD). Objective: To examine the role of autosomal dominant and recessive PD or atypical parkinsonism genes in the risk of iRBD. Methods: Ten genes, comprising the recessive genes PRKN, DJ-1 (PARK7), PINK1, VPS13C, ATP13A2, FBXO7, and PLA2G6 and the dominant genes LRRK2, GCH1, and VPS35, were fully sequenced in 1039 iRBD patients and 1852 controls of European ancestry, followed by association tests. Results: We found no association between rare heterozygous variants in the tested genes and risk of iRBD. Several homozygous and compound heterozygous carriers were identified, yet there was no overrepresentation in iRBD patients versus controls. Conclusion: Our results do not support a major role for variants in these genes in the risk of iRBD. \ua9 2020 International Parkinson and Movement Disorder Society